Precision oncology company developing potentially best-in-class, CNS-penetrant therapeutics
Lengo Therapeutics is a precision oncology company developing CNS-penetrant inhibitors of cancer driver mutations. The company is comprised of experts in kinase biology and drug discovery, and is advancing a pipeline of potentially best-in-class candidates for patients with, or at high risk of, brain metastases.
